BeOne Medicines
ONC
#609
Rank
NZ$74.08 B
Marketcap
NZ$654.95
Share price
1.06%
Change (1 day)
14.06%
Change (1 year)
BeOne Medicines formerly known as BeiGene, is a multinational pharmaceutical company engaged in the R&D, commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

Earnings for BeOne Medicines (ONC)

Earnings in 2026 (TTM): NZ$1.77 Billion

According to BeOne Medicines's latest financial reports the company's current earnings are NZ$6.12 Billion. In 2025 the company made an earning of NZ$0.90 Billion, an increase over its 2024 earnings that were of -NZ$1.01 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for BeOne Medicines from 2015 to 2026

Annual earnings

Year Earnings Change
2026 (TTM) NZ$1.77 B95.82%
2025 NZ$0.90 B-190.03%
2024 -NZ$1.01 Billion-52.95%
2023 -NZ$2.15 Billion-32.52%
2022 -NZ$3.18 Billion24.39%
2021 -NZ$2.56 Billion-13.21%
2020 -NZ$2.95 Billion72.69%
2019 -NZ$1.71 Billion36.01%
2018 -NZ$1.26 Billion616.83%
2017 -NZ$0.18 Billion-15.24%
2016 -NZ$0.21 Billion107.91%
2015 -NZ$99.13 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
OPKO Health
OPK
-NZ$0.15 Billion-107.82%๐Ÿ‡บ๐Ÿ‡ธ USA
Onconova Therapeutics
ONTX
-NZ$32.22 Million-101.78%๐Ÿ‡บ๐Ÿ‡ธ USA